Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas

NCT01553539 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT01553539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01553539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
January 31, 2013
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone cancer, chondrosarcoma, clear cell sarcoma of the kidney, metastatic osteosarcoma, ovarian sarcoma, recurrent adult soft tissue sarcoma, recurrent osteosarcoma, recurrent uterine sarcoma, stage iii adult soft tissue sarcoma, stage iii uterine sarcoma, stage iv adult soft tissue sarcoma, stage iv uterine sarcoma